Nektar Therapeutics to Host Virtual Investor & Analyst Event Transcript
Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Investor and Analyst Event. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jennifer Ruddock, Chief Business Officer. Please go ahead.
Thank you, Crystal. Good morning, everyone, and thank you for joining us on today's analyst call to discuss the final Phase 1 data for REZPEG and atopic dermatitis. Next slide.
Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidate REZPEG, clinical trials results,, the timing of the startup and plans for ongoing or planned clinical trials, the therapeutic potential of our drug candidate, the timing and outcome of regulatory decisions and future availability of clinical trial data. Because these statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |